Patent 11970544 was granted and assigned to Genmab A/S on April, 2024 by the United States Patent and Trademark Office.
The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.